Is giant cell tumor of tendon sheath benign?
Is giant cell tumor of tendon sheath benign?
Giant cell tumor of tendon sheath (GCTTS) is characterized by diffuse proliferation of synovial-like cells and multinucleated giant cells along tendon sheaths. This benign tumor typically presents in the third to fourth decade of life and is exceeding rare in children.
Is giant cell tumor of tendon sheath cancer?
These tumors cause the affected synovium, bursae or tendon sheaths to thicken and overgrow. They are benign, which means they are not cancerous and do not spread to other areas of the body (metastasize). However, they can grow and cause damage to the surrounding tissue and structures of the body.
Can giant cell tumors spread?
While giant cell tumors are typically benign (noncancerous), they can grow quickly and destroy bone close to a joint. In rare cases, a giant cell tumor may spread, or metastasize, to the lungs.
Can giant cell tumor metastasis?
Metastasis in giant cell tumor (GCT) of bone occurs most commonly in the lung, variously reported from 1% to 9% [7, 9, 17, 19, 20]. There have been isolated case reports of its occurrence at different sites, such as the lymph nodes (mediastinum, paraaortic), bone, skin, and breast [1, 6, 9, 13, 14, 21].
How often do giant cell tumors come back?
Clinically, GCT presents as a benign but often aggressive lesion with a tendency toward local recurrence. Depending on the type of treatment and the local presentation of the tumor, recurrence rates range from 0% to 65% (Table 1) [1, 3, 5, 6, 15, 20, 25, 26, 29, 31, 37, 38, 40, 43, 50].
How do you get rid of a giant cell tumor of the tendon sheath?
Because the mass is frequently associated with the tendon sheath or synovial joint, complete excision can be difficult. Often, partial excision of the joint capsule or tendon sheath is necessary for complete removal of the tumor. Meticulous dissection and exploration are essential because satellite lesions are common.
How quickly do giant cell tumors grow?
Giant cell tumor of bone (GCTB) in skeletally immature patients is rare, and little is known regarding how fast GCTB can grow. We report a case of a 10-year-old skeletally immature girl with pathologically proven GCTB with obvious growth plate invasion that showed surprisingly rapid growth over only 14 days.
Which benign bone tumor can metastasize to lungs?
In conclusion, GCTB is normally considered a benign bone tumor. However, it may occasionally metastasize to vital organs such as the lung. The prognosis can be successful with timely and appropriate surgical treatment and chemotherapy.
What percentage of benign giant cell tumors recur?
What percentage of giant cell tumor is malignant?
We identified 4 large series of patients with malignant giant cell tumor of bone that provided data on 2315 patients with giant cell tumor of bone. Across these studies, the cumulative incidence of malignancy was 4.0%; the cumulative incidence of primary malignancy was 1.6% compared with 2.4% for secondary malignancy.
How often do giant cell tumors recur?
What kind of tumor is in the tendon sheath?
Background: Giant cell tumor of the tendon sheath is the most common form of giant cell tumors and is the second most common soft tissue tumor of the hand region after ganglion cyst. Magnetic resonance imaging is the diagnostic tool of choice for both diagnosis and treatment planning.
How often does a tendon sheath tumor recur?
Nineteen of the 70 patients (27%) had a surgically and histologically documented recurrence at an average of 2 years 3 months (range, 3 months to 1 … Seventy patients underwent surgical excision of a giant cell tumor of the tendon sheath. The patients were monitored for an average of 3 years 4 months.
Are there giant cell tumors in the knee?
Localized forms of giant cell tumors are defined as giant cell tumors of the tendon sheath (GCTTS). GCTTS arises from the synovium of a joint, bursa or tendon sheath, and 85% of the tumors occur in the fingers. GCTTS in the knee is extremely rare.
Are there any recurrences of hand tendon tumors?
Three recurrences (6%) were recorded. The only significant risk factor for the recurrence was tumor adjacency to the interphalangeal joints of the fingers other than thumb. No major or minor complications were encountered in the postoperative period.